BioAge Labs, Inc (BIOA) - Total Liabilities
Based on the latest financial reports, BioAge Labs, Inc (BIOA) has total liabilities worth $22.02 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore BIOA strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
BioAge Labs, Inc - Total Liabilities Trend (2013–2025)
This chart illustrates how BioAge Labs, Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see BioAge Labs, Inc assets under control.
BioAge Labs, Inc Competitors by Total Liabilities
The table below lists competitors of BioAge Labs, Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
RDC Semiconductor Co Ltd
TWO:3228
|
Taiwan | NT$112.04 Million |
|
Open Lending Corp
NASDAQ:LPRO
|
USA | $155.77 Million |
|
Anhui Xinbo Aluminum Co Ltd
SHE:003038
|
China | CN¥8.93 Billion |
|
Waterstone Financial Inc
NASDAQ:WSBF
|
USA | $1.90 Billion |
|
Zhejiang Hengwei Battery Co. Ltd.
SHE:301222
|
China | CN¥116.29 Million |
|
Kairuide Holding Co Ltd
SHE:002072
|
China | CN¥21.67 Million |
|
JTL Industries Ltd
NSE:JTLIND
|
India | Rs4.75 Billion |
|
Fine Semitech Corp
KQ:036810
|
Korea | ₩287.68 Billion |
Liability Composition Analysis (2013–2025)
This chart breaks down BioAge Labs, Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See BioAge Labs, Inc balance sheet quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 17.19 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.06 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how BioAge Labs, Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for BioAge Labs, Inc (2013–2025)
The table below shows the annual total liabilities of BioAge Labs, Inc from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $22.84 Million | -34.95% |
| 2024-12-31 | $35.11 Million | -82.39% |
| 2023-12-31 | $199.32 Million | +41.37% |
| 2022-12-31 | $140.99 Million | +195.81% |
| 2017-12-31 | $47.66 Million | -57.76% |
| 2016-12-31 | $112.84 Million | +16.65% |
| 2015-12-31 | $96.73 Million | +1.92% |
| 2014-12-31 | $94.91 Million | +93.42% |
| 2013-12-31 | $49.07 Million | -- |
About BioAge Labs, Inc
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhib… Read more